Munich — Inter­na­tio­nal law firm Clif­ford Chance has advi­sed Welling­ton Part­ners on its successful fund­rai­sing for its fifth fund, Welling­ton Part­ners Life Science Fund V (WPLS‑V). The fund closed at €210 million, making it Welling­ton Part­ners’ largest life science fund to date.

Welling­ton Part­ners is a leading Euro­pean venture capi­tal firm inves­t­ing in early and growth stage life science compa­nies. The funds from WPLS V will be spent on a port­fo­lio of appro­xi­m­ately 15 to 20 compa­nies that are active in biotech­no­logy or are deve­lo­ping new thera­pies and medi­cal devices. Selec­ted invest­ments in diagno­stics and digi­tal health are also part of the invest­ment stra­tegy. The geogra­phi­cal focus is on Europe, in parti­cu­lar the German-spea­king region. In addi­tion, isola­ted invest­ments in North America or Asia are also being considered.

WPLS‑V gained many new well-known inves­tors such as KfW Capi­tal, Talanx and the U.S. UTIMCO, the Univer­sity of Texas/Texas A&M Invest­ment Company. Exis­ting inves­tors such as the Euro­pean Invest­ment Fund and the Euro­pean Invest­ment Bank also participated.

The advi­sing Clif­ford Chance team was led by part­ner Sonya Pauls(photo, Corporate/Private Equity, Munich).

About Clif­ford Chance
Clif­ford Chance, one of the world’s leading law firms, is present for its clients with around 3,400 legal advi­sors in all major busi­ness centers around the world. — In Germany, Clif­ford Chance is repre­sen­ted by around 300 lawy­ers, audi­tors, tax advi­sors and soli­ci­tors in Düssel­dorf, Frank­furt am Main and Munich.